Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated:  11/28/2017
Medical University of South Carolina
mi
from
Charleston, SC
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated: 11/28/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated:  11/28/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated: 11/28/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated:  11/28/2017
Baylor University Medical Center
mi
from
Dallas, TX
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated: 11/28/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated:  11/28/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated: 11/28/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated:  11/28/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated: 11/28/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated:  11/28/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Status: Enrolling
Updated: 11/28/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Iron Overload in Patients Undergoing Donor Stem Cell Transplant
Iron Overload in Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  11/29/2017
University of Minnesota Children's Hospital - Fairview
mi
from
Minneapolis, MN
Iron Overload in Patients Undergoing Donor Stem Cell Transplant
Iron Overload in Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 11/29/2017
University of Minnesota Children's Hospital - Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
Status: Enrolling
Updated:  11/29/2017
Scott and White Cancer Institute
mi
from
Temple, TX
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
Status: Enrolling
Updated: 11/29/2017
Scott and White Cancer Institute
mi
from
Temple, TX
Click here to add this to my saved trials
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
Status: Enrolling
Updated:  11/29/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
Status: Enrolling
Updated: 11/29/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Haploidentical Donor Natural Killer (NK) Cell Infusion With Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Haploidentical Donor Natural Killer (NK) Cell Infusion With Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy in Older Adults With Acute Myelogenous Leukemia in First Complete Remission
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy in Older Adults With Acute Myelogenous Leukemia in First Complete Remission
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy in Older Adults With Acute Myelogenous Leukemia in First Complete Remission
Status: Enrolling
Updated:  11/29/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy in Older Adults With Acute Myelogenous Leukemia in First Complete Remission
Status: Enrolling
Updated: 11/29/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
A Phase II Trial Investigating Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
A Phase II Trial Investigating Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease in Recipients of a Non-Myeloablative Umbilical Cord Blood Transplantation for Treatment of Hematological Malignancies
Status: Enrolling
Updated:  11/29/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease in Recipients of a Non-Myeloablative Umbilical Cord Blood Transplantation for Treatment of Hematological Malignancies
Status: Enrolling
Updated: 11/29/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
Stromal Injury and Clonal Adaptation in Myelodysplasia
Status: Enrolling
Updated:  11/30/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
Stromal Injury and Clonal Adaptation in Myelodysplasia
Status: Enrolling
Updated: 11/30/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.
Status: Enrolling
Updated:  12/1/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.
Status: Enrolling
Updated: 12/1/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Post Transplant Donor Lymphocyte Infusion
Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Post Transplant Donor Lymphocyte Infusion
Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplantation for Hematological Malignancies
Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplantation for Hematological Malignancies
Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Haploidentical Donor NK Cell Adoptive Therapy and Double T Cell Depleted Umbilical Cord Blood Transplantation With Post-Transplant IL-2 Immune Therapy For Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Children's Hospital - Fairview
mi
from
Minneapolis, MN
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Haploidentical Donor NK Cell Adoptive Therapy and Double T Cell Depleted Umbilical Cord Blood Transplantation With Post-Transplant IL-2 Immune Therapy For Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Children's Hospital - Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Amplatz Children's Hospital
mi
from
Minneapolis, MN
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Amplatz Children's Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
A Therapeutic Trial of Bortezomib (Velcade), Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center, University if Minnesota
mi
from
Minneapolis, MN
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
A Therapeutic Trial of Bortezomib (Velcade), Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center, University if Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Adoptive Transfer of Haploidentical Natural Killer Cells to Treat Refractory or Relapsed AML MT2010-02
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Adoptive Transfer of Haploidentical Natural Killer Cells to Treat Refractory or Relapsed AML MT2010-02
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
AHN-12 Biodistribution in Advanced Leukemia
Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 In Patients With Advanced Leukemia HM2010-05
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
AHN-12 Biodistribution in Advanced Leukemia
Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 In Patients With Advanced Leukemia HM2010-05
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Influenza Vaccine Post Allogeneic Transplant
MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Influenza Vaccine Post Allogeneic Transplant
MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Preservation of Ovarian Function After Hematopoietic Cell Transplant
A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Preservation of Ovarian Function After Hematopoietic Cell Transplant
A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
T-Cell Depleted Double UCB for Refractory AML
T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
T-Cell Depleted Double UCB for Refractory AML
T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  12/3/2017
The Mayo Clinic
mi
from
Rochester, MN
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 12/3/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Total Marrow Irradiation for Refractory Acute Leukemia
Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord BloodTransplantation In Patients With Refractory Acute Leukemia
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Total Marrow Irradiation for Refractory Acute Leukemia
Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord BloodTransplantation In Patients With Refractory Acute Leukemia
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/3/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/3/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Single-Center, Open Label, Randomized Trial Comparing StemRegenin-1 Expanded Versus Unmanipulated Umbilical Cord Blood Transplantation In Patients With High-Risk Malignancy
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Single-Center, Open Label, Randomized Trial Comparing StemRegenin-1 Expanded Versus Unmanipulated Umbilical Cord Blood Transplantation In Patients With High-Risk Malignancy
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Allogeneic Natural Killer Cells in Patients With Relapsed Acute Myelogenous Leukemia
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center
mi
from
Minneapolis, MN
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Allogeneic Natural Killer Cells in Patients With Relapsed Acute Myelogenous Leukemia
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated:  12/3/2017
Midwest Children's Cancer Center at Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
Status: Enrolling
Updated: 12/3/2017
Midwest Children's Cancer Center at Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials